• 1. Evidence-based Medicine Center of Lanzhou University, Lanzhou 730000, China;2. School of Basic Medical Science of Lanzhou University, Lanzhou 730000, China;3. The First Clinical College of Lanzhou University, Lanzhou 730000, China;4. School of Public Health of Lanzhou University, Lanzhou 730000, China;
YANG Kehu, Email: yangkh2006@163.com
Export PDF Favorites Scan Get Citation

Objective  To evaluate the quality of diagnostic studies on detecting anti-cyclic citrullonated peptide antibody to diagnose rheumatoid arthritis.
Methods  We searched PubMed, EMbase, The Cochrane Library, and CBM to collect studies on using anti-cyclic citrullonated peptide antibody to diagnose rheumatoid arthritis. QUADAS items were used to evaluate the quality of included studies.
Results  A total of 195 studies were included. Sixty-nine were English studies and 126 were Chinese studies. All studies had good descriptions of the spectrum of patients and little potential for partial verification bias, differential verification bias, and incorporation bias. However, most studies were prone to disease progression bias, review bias, and clinical review bias. One study did not explain the intermediate test results, and another did not report part of the test results. The overall quality of English studies was better than that of Chinese studies.
Conclusion   The potential bias of the included studies mainly resulted from the absence of blinding when interpreting the test results. The reporting quality of the included studies was poor.

Citation: YI Kang,WANG Yunfang,TIAN Jinhui,MA Bin,ZHAO Fenghui,YANG Kehu. Quality Assessment of Diagnostic Studies on Using Anti-cyclic Citrullonated Peptide Antibody to Diagnose Rheumatoid Arthritis. Chinese Journal of Evidence-Based Medicine, 2009, 09(1): 99-106. doi: 10.7507/1672-2531.20090020 Copy

  • Previous Article

    《中国呼吸与危重监护杂志》稿约
  • Next Article

    《中国呼吸与危重监护杂志》稿约